Long-term experience with Burkitt's lymphoma in Uganda

Area of Science:

• Oncology
• Pediatric Oncology
• Hematology

Background:

• Burkitt's lymphoma is an aggressive non-Hodgkin lymphoma with a high incidence in equatorial Africa.
• Understanding long-term outcomes is crucial for improving patient survival and management strategies.

Purpose of the Study:

• To report the cumulative results and long-term follow-up of Burkitt's lymphoma patients treated at the Uganda Cancer Institute.
• To identify prognostic factors influencing remission duration and survival.

Main Methods:

• Retrospective analysis of all Burkitt's lymphoma patients treated at the Uganda Cancer Institute, Kampala.
• Data collection included patient demographics, clinical presentation, treatment protocols, response rates, relapse patterns, and survival outcomes.

Main Results:

• An annual admission rate of 29 patients was observed.
• Common presenting symptoms include jaw swelling (72%), abdominal swelling (56%), and central nervous system involvement (30%).
• An 81% complete response rate was achieved, with 50% of responders relapsing (equal numbers before and after 3 months). Disease stage, treatment protocols, and relapse type influenced outcomes.
• Central nervous system relapse did not preclude long-term survival with appropriate therapy.
• Currently, 25% of treated patients are disease-free survivors beyond 5 years.

Conclusions:

• Burkitt's lymphoma in Uganda presents with specific clinical features and achieves high initial response rates.
• Disease stage is the most critical factor for remission duration and survival.
• Long-term survival is achievable, even after central nervous system relapse, emphasizing the importance of tailored treatment strategies.